Daily Sepsis Research Analysis

BACKGROUND: Pediatric sepsis is a leading cause of global morbidity and mortality, yet high-resolution, granular subnational assessments remain scarce. Chile and Mexico are the only countries in Latin America that possess robust vital registration systems and open access databases with marginal levels of missing cases. This offers a unique opportunity to quantify the subnational burden of pediatric sepsis, identify healthcare system constrictions, and guide targeted public health interventions. METHODS: This retrospective longitudinal study analyzed official hospital discharge and non-fetal death records of pediatrics (< 10 years old) from Chile and Mexico between 2014 and 2024. Age-standardized incidence (ASIR) and mortality (ASMR) rates, standardized ratios, and the mortality-to-incidence ratio (MIR), were calculated to assess mortality relative to subnational hospital output. A novel dynamic risk stratification matrix was developed to classify ICD-10 sepsis-related causes into four risk/severity quadrants based on year-specific ASIR and MIR indicators. RESULTS: A total of 656,234 discharges and 2,035 deaths in Chile, and 964,452 discharges and 77,252 deaths in Mexico were analyzed. Subnational trends were highly heterogeneous. Chile exhibited a predominantly low pediatric MIR (median < 1%) with isolated hotspots with significant structural deviations to the North. High-severity sepsis causes in Chile were relatively rare. Conversely, Mexico displayed an alarmingly high MIR (median 7.2%), with systemic persistency in States such as Chiapas and Nuevo León. Strikingly, high-severity causes in Mexico (e.g., unspecified septicaemia, bacterial meningitis) were highly frequent, accounting for 88-97% of pediatric sepsis deaths. Furthermore, systemic instances of code-specific MIR > 1.0 in Mexico suggest significant health system fragmentation and decoupling of hospital discharge from vital statistic registries. CONCLUSIONS: Pediatric sepsis in Latin America encompasses distinct realities, ranging from localized critical care gaps to high-lethality persistency. One-size-fits-all national policies may be inadequate. These findings advocate for precision public health, urging the deployment of decentralized, data-driven interventions and specialized resource allocation based on high-risk subnational hotspot identification.

BACKGROUND: The serial performance of C-reactive protein (CRP), procalcitonin, and emerging biomarker pancreatic stone protein (PSP) was evaluated for the diagnosis of infection and sepsis in patients admitted to the intensive care unit (ICU). METHODS: All consecutive adult patients with suspected infection or sepsis upon their admission to the ICUs of three multi-speciality hospitals in the UAE were enrolled. CRP, procalcitonin, and PSP levels were measured at admission and repeated within 24-48 h. Patients were categorized into infection vs. non-infection, sepsis vs. non-sepsis groups, and into culture-positive and culture-negative subgroups. RESULTS: A total of 272 ICU patients were analyzed. All biomarkers could be used to distinguish infection with CRP (AUROC 0.77; 95% confidence intervals [CI] 0.70-0.83) and procalcitonin (AUROC 0.75; 95% CI 0.68-0.81) showing fair performance. Moreover, serial monitoring at 24-48 h improved performance, especially for procalcitonin (p = 0.04). Among patients with infection, PSP levels were higher in culture-positive compared to culture-negative patients, but the difference did not reach statistical significance (median 229 vs. 142 ng/ml, p = 0.05). However, all three biomarkers failed to discriminate sepsis with an AUROC of 0.56 (95% CI 0.49-0.64) for CRP, 0.54 (95% CI 0.46-0.62) for procalcitonin, and 0.58 (95% CI 0.50-0.66) for PSP, respectively. Combining biomarkers improved specificity (93.85%) but with reduced accuracy. CONCLUSION: Despite a significant rise in all biomarkers, procalcitonin has overall better performance for diagnosing infections. None of the biomarkers could differentiate sepsis at admission.

BACKGROUND: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are multifaceted clinical conditions characterized by uncontrolled inflammatory responses and compromised integrity of the alveolar-capillary barrier. The lack of specific diagnostic tests and effective pharmacologic therapies for ARDS reflects its underlying biological heterogeneity. In sepsis, the excessive formation of neutrophil extracellular traps (NETs) contributes to ALI pathogenesis by inducing endothelial injury, increasing vascular permeability, and amplifying pulmonary inflammation. This meta-analysis integrates findings from clinical and preclinical studies to elucidate disease pathogenesis and inform diagnostic strategies. METHODS: A systematic search of PubMed, Google Scholar, and the Cochrane Library was conducted following predefined inclusion and exclusion criteria. The primary outcome measure was the standardized mean difference with a 95% confidence interval, assessed using a random-effects model. RESULTS: We identified a significant upregulation of NETs and their related components, including myeloperoxidase (MPO), the MPO-DNA complex, neutrophils, citrullinated histone H3 (citH3), cell-free DNA (cfDNA), double-stranded DNA (dsDNA), and peptidylarginine deiminase 4 (PAD4) in preclinical models. Furthermore, we validated the elevated expression of NETs, cfDNA, dsDNA, and the MPO-DNA complex in patients with ALI/ARDS. CONCLUSION: This meta-analysis identified key NET-associated biomarkers that are dysregulated in both patients with ALI and experimental models. These biomarkers are involved in disease pathophysiology and have the potential to serve as diagnostic indicators. These outcomes contribute to a deeper understanding of NET-mediated mechanisms in ALI and support the need for further research on NET-targeted diagnostic approaches and therapeutic strategies.